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Abstract
Background:  Despite continuing advances in our understanding of AIDS pathogenesis, the
mechanism of CD4+ T cell depletion in HIV-1-infected individuals remains unclear. The HIV-1 Vpr
accessory protein causes cell death, likely through a mechanism related to its ability to arrest cells
in the G2,M phase. Recent evidence implicated the scaffold protein, 14-3-3, in Vpr cell cycle
blockade.
Results: We found that in human T cells, 14-3-3 plays an active role in mediating Vpr-induced cell
cycle arrest and reveal a dramatic increase in the amount of Cdk1, Cdc25C, and CyclinB1 bound
to 14-3-3 θ during Vprv-induced G2,M arrest. By contrast, a cell-cycle-arrest-dead Vpr mutant failed
to augment 14-3-3 θ association with Cdk1 and CyclinB1. Moreover, G2,M arrest caused by HIV-
1 infection strongly correlated with a disruption in 14-3-3 θ binding to centrosomal proteins, Plk1
and centrin. Finally, Vpr caused elevated levels of CyclinB1, Plk1, and Cdk1 in a complex with the
nuclear transport and spindle assembly protein, importin β.
Conclusion: Thus, our data reveal a new facet of Vpr-induced cell cycle arrest involving previously
unrecognized abnormal rearrangements of multiprotein assemblies containing key cell cycle
regulatory proteins.
Reviewers: This article was reviewed by David Kaplan, Nathaniel R. Landau and Yan Zhou.
Background
The HIV-1 accessory protein, viral protein R (Vpr), has
been shown to be important in viral cytopathicity during
virus infection and can kill cells independently when
experimentally expressed [1,2]. It is highly conserved, spe-
cifically packaged into virions, and facilitates HIV-1 repli-
cation in nondividing cells [3], while removal of its
homologues in simian immunodeficiency virus results in
attenuation of virus replication and disease in rhesus
monkeys [4]. The lethal capability of Vpr correlates with
its ability to induce cell cycle blockade in G2,M [2,5-10].
Although multiple mechanisms have been proposed to
explain how Vpr arrests the cell cycle, there is no unifying
theory. For example, the DNA damage sensing kinase,
ATR, the damaged DNA binding protein 1 component of
an E3 ubiquitin ligase, and the scaffolding protein, 14-3-
3, have all been shown to mediate Vpr-induced G2,M cell
cycle arrest [11-17]. Since the majority of these studies
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were performed in non-lymphocyte human cell lines, a
better mechanistic understanding of how Vpr blocks the
cell cycle in lymphocytes could help illuminate the mech-
anism of T cell killing during HIV-1 infection. We thus
investigated the role of 14-3-3 in Vpr arrest in T lym-
phocytes and determined how its function is altered by
Vpr and HIV-1 infection.
Progression through the mitotic cell cycle in mammalian
cells is controlled by a group of serine/threonine protein
kinases termed cyclin-dependent kinases (Cdks) that are
activated as a heterodimeric complex with a partner from
the family of cyclin proteins. Cdk1-CyclinB is responsible
for regulating several events during the G2,M transition
and progression through mitosis, including chromosome
condensation, Golgi network fragmentation, and break-
down of the nuclear lamina. Specific functional substrates
include microtubule-binding proteins and proteins
involved in translation, ubiquitin-dependent proteolysis,
and Cdk1 regulation (e.g. Cdc25 phosphatases). Several
negative and positive regulators of both Cdk1 and Cyclins
affect kinase activity under normal cycling and cellular
stress conditions. For example, Wee1 and Myt1 kinases
inhibit Cdk1 activity through phosphorylation of threo-
nine and tyrosine residues, while Cdc25 phosphatases
restore activity by dephosphorylation of these residues.
Phosphorylation of CyclinB1 is also important for Cdk1-
CyclinB activity, as this is required for rapid nuclear entry
of CyclinB1 at the end of prophase preceding nuclear
envelope breakdown [18]. This gives Cdk1-CyclinB access
to key nuclear mitotic substrates.
The 14-3-3 scaffolding proteins have also been implicated
in regulation of the G2,M phase of the cell cycle. These
small, acidic polypeptides of 28–32 kD are highly con-
served, expressed in all eukaryotic organisms, and consist
of seven different isoforms encoded by distinct genes in
mammals with a variety of biological functions. Acting as
either hetero- or homodimers, 14-3-3 proteins bind to
specific phosphoserine and phosphothreonine sequence
motifs and regulate target protein function by compart-
mental sequestration, altered enzymatic activity, or inhi-
bition/promotion of protein-protein interactions. 14-3-3
regulates the G2,M transition by at least two mechanisms:
cytoplasmic sequestration of the Cdk1 activating phos-
phatase, Cdc25C, during most of the natural cell cycle
[19,20], as well as cytoplasmic sequestration of Cdk1
itself following DNA damage [21,22]. Recent evidence
demonstrated that Vpr- induced G2,M arrest is mediated
by Vpr binding to 14-3-3, which allows 14-3-3 to bind
and inhibit unphosphorylated Cdc25C, preventing Cdk1
activation [11]. As these studies were based on overexpres-
sion systems and are conducted in yeast or non-T cell
lines, extension of these findings to a more physiological
system would help improve our understanding of this
important event.
Methods
Cell lines and cell cultures
Jurkat T cells were maintained in RPMI complete medium
(RPMI 1640 BioWhitaker) supplemented with 10% fetal
calf serum (FCS), 100 U/ml penicillin/streptomycin, 2.4
mM L-glutamine, and 50 μM β-mercaptoethanol. All Jur-
kat experiments were conducted using a CD4hi Jurkat sub-
clone, Jurkat 1.9, generated by single-cell sorting of a low
CD4-expressing parental JAK3 cell line [23]. 293T cells
were maintained in Dulbecco's modified Eagle's medium
(DMEM) supplemented as described above. Adriamycin
was added to cultures at 0.2 μg/ml (Sigma) for indicated
durations. Cells were synchronized in the cell cycle by
treatment with aphidicolin (Sigma; 0.75 μM) for 16
hours, after which cells were released from the block for
10 hours and then subjected to an additional 16 hour
block [24].
Transfection
Transient transfection of Jurkat cells with Vpr expression
constructs was performed by electroporation using the
Electro Cell Manipulator™ (BTX) apparatus. 4 × 106 cells
resuspended in 0.4 ml of growth medium and 10–15 μg
of DNA were electroporated in a 4 mm gap cuvette (Bio-
Rad) at 260 V and 1060 microfarads, followed by imme-
diate recovery in growth media for 2–4 days. Transfection
efficiency was routinely between 60–80% as determined
by flow cytometric analysis of GFP-expressing cells 48
hours post transfection. Typically GFP was co-transfected
with other expression plasmids at a ratio of 1:3.3 (e.g. 3 μg
GFP with 10 μg pCDNA3-hVpr) as a marker of transfected
cells.
HIV virus stock and infections
HIV viral plasmids were obtained from the NIH AIDS
Research & Reference Reagent Repository (ARRRP) unless
otherwise indicated. HIV-1 viral stocks of NL4-3n-GFP
(pNLnGFP-Kp; gift of H. Akari; [25]) were prepared from
cell-free supernatant from 293T cells transfected with
plasmid using ExGen (Fermentas) according to the manu-
facturer's recommendations. The env gene was mutated to
make NL4-3e- derivatives for one-round infection pur-
poses by either blunt-end filling of the Nde I site or the
Kpn I site in the proviral sequence. env- derivatives of NL4-
3 were pseudotyped by cotransfection of 293T cells with
pLVSV-G at a ratio of 2 μg HIV to 0.5–1 μg pLVSV-G. Viral
stocks were harvested 48 hours after transfection, stored at
-80°C, and viral titers were assessed by functional MOI
determination based on the Poisson distribution (f(x) = e-
λλx/x! where x is a random variable). Using this model, the
predicted frequency of 63.2% infected cells is expected
after inoculation with a multiplicity of infection (MOI)Biology Direct 2008, 3:17 http://www.biology-direct.com/content/3/1/17
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equal to 1 in a single-round infection. Virion Vpr (Vprv)
was delivered to Jurkat cells by either pre-treating target
cells with 3TC (10 μM; ARRRP) for 24 hours or using a
reverse transcriptase inactive mutant (D186N, RT-; gift of
E. Freed, National Cancer Institute, NIH) derivative of
NL4-3. Additional viral strains included Vif- [26], Vpr-
(deletion mutant of amino acids 22–81), and Vif-Vpr-
NL4-3e-n-GFP. Typically, Jurkat cells were inoculated at an
MOI of 2–5 in 12-well (8 × 105 cells/well) or 24-well (4 ×
105 cells/well) plates for small-scale infections or in T75
flasks (25 × 106 cells) for immunoprecipitation and cell
fractionation experiments in the presence of polybrene (5
μg/ml; Sigma). Virus was adsorbed for 30 minutes at
37°C, 5% CO2 followed by centrifugation for 30 minutes
at 800 × g. Cultures were maintained at 5–10 × 105 cells/
ml by feeding and splitting cultures as needed.
Assays for viral production, cell viability, and cell cycle
HIV-1 cytopathicity was assessed by flow cytometric for-
ward and side light scatter or forward scatter and propid-
ium iodide (PI; Sigma) profiles of at least 10,000 live cells
daily throughout the course of infection (FACScalibur,®
Becton Dickinson). All FACS data analysis was performed
using FlowJo software (Tree Star, Inc.). Simultaneously,
these samples were measured for HIV-1 provirus expres-
sion by GFP fluorescence. Infected viable cell counts were
measured by collection for a constant period of time (50
seconds) per sample. To measure DNA content, cells were
fixed in 1% paraformaldehyde (in PBS) for 10 minutes,
washed once in PBS, resuspended in 70% ethanol while
gently mixing, incubated at -20°C for 30 minutes or over-
night, washed in PBS, and resuspended in 200 μl DNA
staining solution (5 μg/ml PI, 50 μg/ml RNase, 0.45 mg/
ml sodium citrate, in PBS) for 30 minutes at 25°C. Alter-
natively, cells were stained with 10 μM of the cell-perme-
able DNA dye, DRAQ5 (Axxora, San Diego), for 5 min at
37°C according to the manufacturer's instructions.
Stained cells were processed on a FACScalibur® or FACS-
can (Becton Dickinson) and using the doublet discrimina-
tor module (DDM) to exclude cells with DNA signal
width greater than the bulk cell population.
siRNA knockdowns
Jurkat T cells were electroporated as described above with
500 pmol siRNA (Invitrogen Stealth™ RNAi, unless other-
wise noted). Target sequences were as follows: 14-3-3 θ
59: UUCUGCUCGAUGCUGAGAUGACCC, 14-3-3 θ 60:
UUCGAUCAUCACCACACGCAACUUC, 14-3-3 η 39:
UGAUCAGGAACUUGUC
AAGCAGAGA, 14-3-3 β 34: UUAGUGCCAGACCAAGAC-
GAAUUGG, 14-3-3 γ 36: UUCGUUCCUCAUUC-
GACAGUGGCUC, 14-3-3 ζ 42:
AGUAAUUGCAUUAUUA
GCGUGCUGU. Chk1 was targeted using Dharmacon
SMARTpool™ siRNA (sequence not provided). Cultures
were replenished with fresh media 2 days after transfec-
tion and cell density maintained between 5–10 × 105/ml.
Cells were infected with HIV 4 days post-transfection and
knockdown of protein was assessed by western blot.
Immunoprecipitation and immunoblotting
For standard western blotting (WB), whole cell protein
extracts were prepared by lysis for 30 minutes on ice in
modified Laemmli buffer (60 mM Tris, pH 6.8, 10% glyc-
erol, and 2% sodium dodecyl sulfate (SDS)), followed by
DNase (Benzonase® nuclease; Novagen) treatment for 30
minutes. The detergent-insoluble fraction was pelleted by
centrifugation at 16,000 × g in an Eppendorf centrifuge for
10 min at 4°C and supernatants boiled in SDS loading
buffer (50 mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol,
12.5 mM EDTA, 0.02% bromophenol blue) and 20 mM
dithiothreitol (DTT). Samples containing equal cell num-
bers were electrophoresed on a 4–20% Tris/glycine/SDS
gel (Novex™) and blotted onto nitrocellulose using a sem-
idry transfer apparatus using the manufacturer's proce-
dure (Biorad).
For immunoprecipitation (IP) experiments, cells were
lysed with a mild Nonidet P-40-based IP buffer (0.2%
Nonidet P-40, 150 mM NaCl, 10 mM Tris-HCl pH 7.5) for
30 minutes with gentle mixing, normalized for protein
concentration quantitated by the BCA™ Protein Assay Kit
(Pierce), pre-cleared with Protein G-Agarose (Roche) for
30 minutes, and immunoprecipitated with 3–5 μg anti-
body for 3 to 6 hours. All steps were performed at 4°C
with gentle mixing. Generally, 2–4 mg lysate was used for
each IP experiment and an input sample was set aside fol-
lowing the pre-clear step. IP pellets were washed three
times in lysis buffer and eluted with SDS loading buffer
and separated by SDS polyacrylamide gel electrophoresis
(SDS-PAGE) as above.
Cross-linking experiments were performed by treatment
of live cells with 1 or 5 mM disuccinimidyl suberate (DSS,
Pierce) for 30 minutes at 25°C followed by quenching by
addition of 50 mM glycine for 15 minutes at 25°C. Cells
were washed in phosphate buffered saline (PBS) twice fol-
lowed by lysis in IP buffer for 30 minutes at 4°C. Lysates
were cleared by centrifugation at 2,000 × g for 10 minutes
and 120 μg protein was separated on 3–8% Tris-acetate
gel (Invitrogen) run in Tris-acetate running buffer (Invit-
rogen) on ice. Protein was transferred to a nitrocellulose
membrane using NuPAGE transfer buffer (Invitrogen) for
two hours and blotted as described below.
Cytoplasmic and nuclear separation extracts were pre-
pared by initial lysis in Buffer A (10 mM HEPES, pH 7.9,
10 mM KCl, 0.1 mM EDTA, 0.4% Nonidet P-40, 1.5 mMBiology Direct 2008, 3:17 http://www.biology-direct.com/content/3/1/17
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MgCl2, 0.5 mM phenylmethylsulphonylfluoride (PMSF),
and 0.5 mM DTT; 0.2 mL/2 × 106 cells) for 5–10 minutes
on ice. Nuclei were pelleted by centrifugation at 750 × g
for 5 minutes and the cytoplasmic extract (supernatant)
was retained. Nuclei were lysed with Buffer C (20 mM
HEPES pH 7.9, 420 mM NaCl, 1.5 mM MgCl2, 25% glyc-
erol, 0.2 mM EDTA, 0.5 mM PMSF, and 0.5 mM DTT; 20
μl/2 × 106 cells) for 10–30 minutes on ice mixing as nec-
essary, vortexed vigorously for one minute, and centri-
fuged at 12,000 × g for 10 minutes yielding nucleoplasm
in the supernatant. Lysates were separated by SDS-PAGE
as above.
Blots were blocked with 2.5% nonfat dry milk in 0.1%
PBS-Tween 20 (PBS-T), probed with primary antibody,
followed by HRP-conjugated secondary antibody diluted
1:10,000, with three five minute washes in PBS-T after
each 30 minute incubation. All antibody probes were per-
formed in 2.5% nonfat dry milk, 0.1% PBS-T. Blots were
stripped with Re-Blot Plus Mild (Chemicon International)
for 20 minutes and blocked again before reprobing. Bands
were imaged with Enhanced Chemiluminescent substrate
(Amersham) or SuperSignal® West Dura (Pierce). Com-
plete Protease Inhibitor Cocktail (Roche Diagnostics) was
included in all lysis buffers and the Phosphatase Inhibitor
Cocktail Set I (Calbiochem) was added to all lysis buffers
used in immunoprecipitation experiments. Antibodies
used with corresponding catalog numbers are as follows:
β-actin (Sigma; A5441), Cdc2 (Santa Cruz; sc-54), Phos-
pho-Tyr15-Cdc2 (Cell Signaling; 9111), Cdc25C (BD
Pharmingen; 550922), Cdc25C (Santa Cruz; sc-327),
Cdc25C (Calbiochem; CC26; EMSA), Phospho-Ser216-
Cdc25C (Cell Signaling; 4901), Centrin (Sigma; C7736),
CyclinB1 (Santa Cruz; sc-752 or sc-245), GAPDH
(Abcam; ab9484), PARP (BD Transduction Laboratories;
P76420), importin β (Sigma; I2534) PKA (Santa Cruz; sc-
903), Plk1 (Upstate; 05–844), γ-Tubulin (Sigma; T3559);
HIV-1 Vif (NIH ARRRP; 6459), HIV-1 Vpr (gift of K.
Strebel, NIAID), 14-3-3 β (Santa Cruz; sc-25276), 14-3-3
θ (Santa Cruz; sc-732), 14-3-3 γ (Santa Cruz; sc-731c), 14-
3-3 ζ (Santa Cruz; sc-1019; cross-reacts with β and σ iso-
forms).
Centrosome isolation
Centrosomes were isolated as previously described [27]
with minor adaptations. Briefly, 50 × 106 Jurkat T cells
were treated with 1 μg/ml cytochalasin D and 0.2 μM noc-
odazole for 1 hour at 37°C then washed twice in PBS fol-
lowed by lysis in 5 ml 0.5% NP40 lysis buffer (1 mM
Tri1mM Tris-HCl pH 8.0, 0.5% NP40, 0.5 mM MgCl2,
protease inhibitor, 0.1% 2-mercaptoethanol, phosphatase
inhibitor) for 5 minutes on ice. Nuclei and chromatin
were pelleted at 2,500 × g for 10 minutes and the superna-
tant was filtered through a 70 μm mesh nylon cell strainer
(BD Falcon). PIPES buffer was added to 10 mM and
DNase I (Pharmacia) added at 2 units/ml and lysates
incubated 30 minutes on ice. 3.5 ml of lysate (~20 mg)
was loaded onto a discontinuous sucrose gradient (0.5 ml
70%, 0.3 ml 50%, and 0.3 ml 40% sucrose) in SW55 Ti 5
ml ultracentrifuge tubes (Beckman). All sucrose solutions
were prepared w/w in 10 mM PIPES, 0.1% TritonX-100,
0.1% BME. Samples were centrifuged at 120,000 × g for 1
h at 4°C. The bottom of the tube was gently pierced with
an 18-guage needle and fractions were harvested drop-
wise collecting ~200 μl per fraction for 7 fractions. Frac-
tions were diluted into 1 ml 10 mM PIPES and incubated
30 minutes at 4°C with gentle mixing to dissolve the
sucrose. Centrosomes were recovered by centrifugation at
16,000 × g for 10 minutes.
Results
14-3-3 and Chk1 mediate Vpr G2,M cell cycle block in 
CD4+ T cells
The mechanism by which HIV-1 Vpr blocks the cell cycle
remains unclear. It was previously shown that the σ and η
isoforms of 14-3-3 bind HIV-1 Vpr and play an important
role in mediating the G2,M cell cycle arrest in the human
non-T cell lines, HeLa, HEK 293, and HCT116 [11]. We
therefore began our investigation by testing whether
siRNA targeting of the various isoforms of 14-3-3 could
mitigate Vpr-induced G2,M blockade in the CD4+ Jurkat T
cell leukemia line. The viral strains used to carry out these
studies are shown in Fig. 1A. Since 14-3-3 σ is not
expressed in T cells and 14-3-3 θ (or τ) was initially iden-
tified as an isoform that uniquely bound active but not
inactive Vpr mutants [11,28], we focused on the θ isoform
and observed a partial reduction (50–60%) in Vpr-
induced G2,M arrest upon 14-3-3 θ knockdown as indi-
cated by the decreased ratio of G2,M to G1 cells (Fig. 1B,C).
Nonspecific siRNA, used as a negative control, did not
impair the arrest activity. Silencing of Chk1, the DNA
damage checkpoint kinase involved in Vpr cell cycle
blockade [17], attenuated arrest to the same degree as 14-
3-3 θ (Fig. 1B,C). Immunblotting showed a significant
reduction of the 14-3-3 θ and Chk1 proteins after RNAi
knockdown (Fig. 1D). Similar results were obtained when
either virion-delivered Vpr (Vprv,from virus particles that
enter cells but cannot establish a productive infection) or
endogenously expressed proviral Vpr (NL4-3 Vif-) was
used to test Vpr activity. 14-3-3 silencing was generally less
potent against proviral Vpr-induced arrest, most likely due
to greater Vpr abundance in actively infected cells (data
not shown and Fig. 2A). A Vif-deficient strain of NL4-3
was used to assay the activity of Vpr expressed in infected
cells because Vif has been shown to independently arrest
cells in G2,M [26]. However, 14-3-3 θ knockdown did pro-
tect against HIV-1-mediated G2,M block when both Vif
and Vpr were intact, although to a lesser extent than that
observed in the absence of Vif. This suggests that Vif likely
causes G2,M accumulation by a mechanism that does notBiology Direct 2008, 3:17 http://www.biology-direct.com/content/3/1/17
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Decreased expression of 14-3-3 θ, β, γ, and Chk1 protects against Vprv- and HIV-1 (vif-)-induced cell cycle arrest Figure 1
Decreased expression of 14-3-3 θ, β, γ, and Chk1 protects against Vprv- and HIV-1 (vif-)-induced cell cycle arrest. (A) Diagram of the basic HIV-1 genomes 
used throughout the study. Env-deficient NL4-3, NL4-3e-n-GFP, (top) also lacks nef, which was replaced with EGFP. Vpr protein associated with virions 
(Vprv) was delivered into cells using an RT point mutant, D186N, derivative of NL4-3e-n-GFP (bottom). (B) Jurkat T cells were transfected with 500 pmol of 
nonspecific (ns), 14-3-3 θ, or Chk1 siRNA and four days later mock-infected or infected with either NL4-3e-n-GFP (NL4-3), NL4-3e-n-GFP Vif- (NL4-3 vif-), or 
RT- NL4-3e-n-GFP (Vprv). Cell cycle arrest by was measured by flow cytometric detection of DRAQ5 DNA staining 44 hours post-infection. DNA analysis 
of cultures infected with RT+ NL4-3e-n-GFP was restricted to actively infected GFP+ cells. Data is representative of six independent experiments. (C) The 
Dean-Jett-Fox cell cycle model was used for determination of G1 and G2,M populations and the ratio is plotted for the FACS data in (B). The transfected 
siRNA is indicated in the legend. (D) Western blot detection of 14-3-3 θ and Chk1 expression four days post-transfection for the samples in (B) and (C). 
β-actin was probed as a loading control. (E) Live cell counts were measured for mock-infected and Vprv-infected samples in (B-D) at the indicated times 
after infection by flow cytometric constant time acquisition. (F) Jurkat cells were transfected as in (B) with the addition of a co-transfected sample that 
received both 14-3-3 θ and Chk1 siRNA (θ + Chk1). Western blot analysis of 14-3-3 θ, Chk1, and β-actin, as a loading control, is shown. (G) Cell cycle 
analysis as in (C) for the samples in (F).
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rely on 14-3-3 θ or Chk1. Thus there are apparently redun-
dant mechanisms for the virus to exert this prominent
effect on the cell cycle. We corroborated the G2,M arrest
alleviation by measuring cell proliferation kinetics (Fig.
1E). While Vprv severely halted cell division in nonspecific
siRNA cultures over time, 14-3-3 θ and Chk1 knockdown
partially rescued cell expansion, consistent with reduced
G2,M accumulation in Fig. 1B.
Since 14-3-3 can function as self-dimers or heterodimers
with other 14-3-3 isoforms [29-31], and additional iso-
forms have been shown to bind active Vpr [11], we deter-
mined whether other 14-3-3 isoforms play a role in Vpr
cell cycle blockade in T cells. Targeting β, η, γ, and ζ iso-
forms by RNAi revealed that 14-3-3 β and γ knockdown
also partially rescued Vpr-induced G2,M arrest, although
to a lesser degree than 14-3-3 θ knockdown (data not
shown). Hence, the θ, β, and γ isoforms of 14-3-3 as well
as the checkpoint kinase, Chk1, are important for mediat-
ing the G2,M arrest caused by Vpr, implicating the DNA
damage checkpoint response. Attempts to silence Chk1
and 14-3-3 θ simultaneously impaired knockdown effi-
ciency for 14-3-3 θ (Fig. 1F), but the lack of any further
decrease in the G2,M/G1 ratio relative to silencing of either
gene alone suggests that Chk1 and 14-3-3 θ likely mediate
Vpr cell cycle block through the same molecular pathway
(Fig. 1G).
Induction of a multiprotein complex containing 14-3-3 θ 
and G2,M regulatory proteins by Vpr and HIV-1 infection
Several cell cycle regulatory functions have been described
for 14-3-3 proteins, including cytoplasmic sequestration
of the G2,M regulatory proteins, Cdc25C and Cdk1
(Cdc2), which limits entry into mitosis [19-22]. To deter-
mine if 14-3-3 interactions were altered by Vpr or HIV-1
infection, we examined the association of 14-3-3 θ with
Cdk1, CyclinB1, and Cdc25C by co-immunoprecipitation
(IP). Vprv significantly increased the amount of Cdk1 and
Increased Cdk1, Cdc25C and CyclinB1 association with 14-3-3 θ but stable nucleocytoplasmic distribution during HIV- and  Vpr-induced G2,M arrest Figure 2
Increased Cdk1, Cdc25C and CyclinB1 association with 14-3-3 θ but stable nucleocytoplasmic distribution during HIV- and 
Vpr-induced G2,M arrest. Jurkat cells were infected as in Fig. 1 with RT- NL4-3e-n-GFP virions either with (Vprv) or without (Δ) 
hVpr supplied in trans or with RT+ NL4-3e-n-GFP (HIV; MOI 2). (A) Cell lysates were harvested two days post-infection for 
immunoprecipitation with 14-3-3 θ and immunoblotting for CyclinB1, Cdc25C-P.S216, Cdc25C, Cdk1-P.Y15, Cdk1, 14-3-3 θ, 
and Vpr as indicated. The 14-3-3 θ signal in the IP does not reflect poor immunoprecipitation of 14-3-3 θ but rather the result 
of membrane stripping prior to 14-3-3 θ blotting. (B) DNA content analysis (y-axis) is shown in flow cytometric dot plots 
against GFP (x-axis) on the right and as a histogram in the inset for the samples in (A). Note that the y-axis of the parent graph 
becomes the x-axis of the inset graph. The quadrant gate demarcates approximate G1 (lower) and S/G2,M (upper) populations 
and the percentage of cells in each relevant quadrant is indicated. The DNA histogram profile analysis was separated into GFP-
positive (+) and negative (-) populations by the x-axis gate for the HIV-infected culture; as expected the infected cells (+) show 
G2 arrest, but the uninfected cells (-) are mostly G1. (C) G2,M cell cycle arrest caused by Vprv and HIV infection does not alter 
the cytoplasmic and nuclear distribution of 14-3-3 θ, Cdc25C, Cdk1, and CyclinB1. Jurkat T cells shown in (A-B) that were 
infected with NL4-3e-n-GFP RT- Δ Vpr (Δ), RT- wt Vpr (Vprv), or NL4-3e-n-GFP RT+ (HIV) for two days were lysed and biochem-
ically separated into cytoplasmic and nuclear fractions. Lysate fractions were blotted as in (A) (the lower panel of Vpr blot rep-
resents a longer exposure in which Vprv is more apparent), with the addition of probes for HIV-1 Vif, Poly(ADP-ribose) 
polymerase (PARP) as a nuclear marker, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a cytoplasmic loading 
control. Cell cycle profiles and GFP expression are shown in (B). (D) Viral lysates (20 μg) of RT- NL4-3e-n-GFP virions with (+) 
or without (-) Vpr were western blotted for CyclinB1, Cdk1, p24, and Vpr as indicated.
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CyclinB1 associated with 14-3-3 θ (Fig. 2A, right panels,
IP). Moreover, the Cdk1 associated with 14-3-3 θ included
a substantial amount of inactive Cdk1 phosphorylated on
tyrosine 15 (P-Y15) (Fig. 2A). Similarly, inactive Cdc25C
phosphorylated on serine-216 (P-S216) showed
increased association with 14-3-3 θ upon Vprv delivery.
Actual HIV-1 infection (RT+) had the same effect,
although this result was variable and occasionally less
Cdk1 and CyclinB1 were recruited to 14-3-3 θ compared
to Vprv treatment (Fig. 2A, HIV lane). This could be due to
opposing effects of other HIV-1 proteins that alter the cell
cycle, such as Vif or Tat [26,32]. The difference, however,
cannot be explained by insufficient Vpr protein since its
expression was markedly greater in HIV-infected cells (Fig.
2A, input). Moreover, the G2,M blockade was comparable
in the Vprv and HIV-infected cultures (Fig. 2B). Note that
cells exposed to Vprv are not GFP positive because they do
not express a provirus due to an inactive RT and there is
not sufficient GFP in the inoculating virions to "donate"
fluorescence. Intriguingly, proportionately more high
molecular weight CyclinB1, presumably hyperphosphor-
ylated "active" CyclinB1 [18,33], was associated with 14-
3-3 θ in HIV-infected samples (Fig. 2A, IP). This upper
band was more apparent in the IP than in the whole cell
lysate, and thus likely represents a small fraction of total
cellular CyclinB1. Thus the virus may drive the active form
of CyclinB1 into complex with 14-3-3. This same event
could also occur with Vprv but the levels may be too low
to detect.
Vpr was also readily observed in the 14-3-3 θ IP (Fig. 2A,
HIV) confirming their association [11]. In contrast to HIV
infection, Vpr protein delivered by the virion, i.e. Vprv,
was generally low or undetectable in the 14-3-3 θ IP (Fig.
2A, IP, Vprv). Thus, the Vpr-14-3-3 θ complex is not obvi-
ously stoichiometric with respect to the quantity of Vpr
bound to 14-3-3. The augmented levels of Vpr in the com-
plex during HIV infection conditions may reflect Vpr oli-
gomers forming during infection when the protein is
more abundant (Fig. 2A, input) [34], as Vpr self-associa-
tion may be concentration-dependent. In summary, Vpr
appears to spark the formation of a multiprotein complex
containing 14-3-3 θ, Cdk1, Cdc25C, CyclinB1, and itself.
However, the possibility that 14-3-3 θ associates inde-
pendently with one or more of these proteins rather than
as a holo-complex is also a formal possibility.
Localization of cell cycle regulatory proteins is not altered 
by Vpr or HIV infection
Although initial work describing 14-3-3 interaction with
Vpr suggested that 14-3-3 binding and cytoplasmic
sequestration of Cdc25C became more promiscuous in
the presence of Vpr [11], we did not observe any gross
changes in the cytoplasmic and nuclear distribution of
multiple cell cycle proteins, including CyclinB1, Cdk1,
Cdk1-P.Y15, Cdc25C-P.S216, and 14-3-3 θ [Additional
file 1A]. As expected, inactive Cdc25C-P.S216 was pre-
dominantly cytoplasmic, presumably due to 14-3-3
sequestration during normal cell cycling through G1
phase [35]. Total Cdc25C appeared to have the same
localization pattern as Cdc25C-P.S216, but possible resid-
ual signal from the phospho-probe made these data diffi-
cult to interpret (data not shown). The cytoplasmic purity
was confirmed by absence of the nuclear protein,
Poly(ADP-ribose) polymerase (PARP). Thus, recruitment
to 14-3-3 does not alter the nucleocytoplasmic distribu-
tion of CyclinB1, Cdk1, or phosphorylated Cdc25C.
Although nuclear levels did not change, Vprv, but not HIV-
1 infection, significantly increased cytoplasmic expression
specifically of CyclinB1 and Polo-like kinase 1 (Plk1), but
not Cdc25C and Cdk1. Plk1, a centrosome-associated
mitotic kinase, participates in several mitotic processes
including centrosome maturation, Cdc25C activation,
inactivation of the Cdk1 inhibitory kinase, Myt1, activa-
tion of CyclinB1, and degradation of mitotic Cyclins [36-
40]. Furthermore, as we also found in the whole cell
lysates in Fig. 2A, the level of Vpr in the cells following vir-
ion delivery, Vprv, is markedly less than during HIV-1
infection and barely detectable by western blotting [Addi-
tional file 1A]. Nevertheless, Vprv causes G2,M blockade as
profound as that observed in infected cells (Fig. 2B). Thus,
Vprv has additional biological effects on CyclinB1 and
Plk1 cytoplasmic protein levels, possibly through regula-
tion of their synthesis, subcellular distribution, or cyto-
plasmic half-life. It is also possible that the increase in
cytoplasmic CyclinB1 and Plk1 reflects protein delivered
into cells by HIV-1 virions rather than endogenously pro-
duced protein as discussed earlier. To explore this hypoth-
esis, we examined the contents of HIV-1 (NL4-3RT-)
virions by Western blot analysis. Both CyclinB1 and Cdk1
were present [Additional file 1B], but Plk1 was not
detected (data not shown). Moreover, the level of these
proteins in the virions was unaltered by the presence of
Vpr making it unlikely that virion-delivered protein
accounted for the elevation. Rather, the elevated CyclinB1
and Plk1 are most likely derived from endogenous sources
in the target cell. Since both CyclinB1 and Plk1 are present
in mammalian centrosomes and Vpr causes abnormal
centrosome duplication [41-43], these findings could also
reflect augmented protein associated with centrosomes.
However, the centrosomal marker, centrin, was not simi-
larly increased by Vprv (data not shown).
Induction of a 14-3-3 θ complex is specific to G2,M 
arresting Vpr
Since cell cycle perturbations are exerted by Vif, Vpr [26],
and possibly other more complicated events during a full
HIV infection, we focused on the virion-delivered Vprv sys-
tem to study the Vpr-specific effect on 14-3-3 bindingBiology Direct 2008, 3:17 http://www.biology-direct.com/content/3/1/17
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partners. We first compared Vpr mutants for their ability
to drive mitotic proteins into the 14-3-3 θ complex. We
found that the well-established R80A point mutant of
Vpr, which lacks G2,M arrest activity [44], failed to
increase Cdk1 and CyclinB1 association with 14-3-3 θ
(Fig. 3A, IP; Fig. 3B, top row). Similar results were
obtained with the inactive S79A mutant (data not
shown). By contrast, both wild-type Vpr and the point
mutant, I70S, which does not affect G2,M-blocking func-
tion [34] (Fig. 3B, top row), increased the complex of
Cdk1, CyclinB1, as well as Plk1, with 14-3-3 θ. Western
blots showed that similar amounts of mutant and wild-
type Vpr protein were delivered (Fig. 3A, input). There was
a marked increase in CyclinB1 and Plk1 total protein dur-
ing G2,M arrest by Vpr (Fig. 3A, input, wt and 70S), likely
due to enhanced expression of cyclic proteins in pre-
mitotic cells, whereas Cdk1 expression was relatively sta-
ble. Thus a general increase in protein level could account
for augmented 14-3-3 θ association with Cyclin B1 and
Plk1 but not Cdk1. To determine if the recruitment was
specific, we probed the 14-3-3 θ IP for additional cell cycle
regulatory proteins. However, we were unable to detect
Chk1, Wee1, or Myt1 (data not shown). Intriguingly, the
Cdk1 activating kinase, Cdk7 [45], clearly associated with
14-3-3 θ (Fig. 3A, IP), suggesting that 14-3-3 θ may func-
tion as a platform for Cdk1 modification by binding mul-
tiple mitotic regulators. Since Cdk7 levels in the IP were
unaltered by Vprv-induced G2,M arrest, though, the
increased recruitment of Cdk1, CyclinB1, and Plk1 to 14-
3-3  θ does not extend to all 14-3-3-binding partners.
Mutant Vpr fails to stimulate the association of CyclinB1, Cdk1, and Plk1 with 14-3-3 θ but still binds 14-3-3 θ itself Figure 3
Mutant Vpr fails to stimulate the association of CyclinB1, Cdk1, and Plk1 with 14-3-3 θ but still binds 14-3-3 θ itself. (A) Jurkat 
cells were infected as in Fig. 2 with RT- NL4-3e-n-GFP virions (Vprv) lacking Vpr (Δ) or containing either wild-type (wt), R80A 
mutant (80A), or I70S mutant (70S) Vpr. Cells lysates were harvested two days post-infection. for immunoprecipitation with 
14-3-3 θ antibody (IP: 14-3-3 θ) and the lysates (input) and IP were blotted as indicated with antibodies recognizing Plk1, 
CyclinB1, Cdk7, Cdk1, 14-3-3 θ, and Vpr. (B) DNA content analysis of the samples in (A), top row (Vprv), and of aphidicolin-
synchronized Jurkat cells released from the G1 block for the indicated number of hours (bottom row; sync.). (C) Immunopre-
cipitation and western blot were performed as in (A) of lysates from the cell cycle synchronized cells shown in (B, bottom 
row). (D) Jurkat cells were infected with NL4-3e-n-GFP (RT+) derivatives containing either wild-type Vpr and Vif (lane 1), Vpr 
but no Vif (lane 2), neither Vpr nor Vif (lane 3), or R80A mutant Vpr and no Vif (lane 4). Two days post-infection cells were 
lysed, immunoprecipitated, and immunoblotted as in (A) (top). Flow cytometric DNA content analysis was performed at the 
time of harvest and shown for the GFP+ (HIV-infected) population of each sample (bottom, numbering corresponds to lane 
numbers of blots). GFP expression is shown as an inset with the percentage of cells in the GFP-positive gate indicated within 
the plot.
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Taken together, these data indicate that induction of
Cdk1-14-3-3 θ association depended on the active version
of Vpr.
To distinguish whether Vpr induces a high molecular
weight (MW) complex(es) or multiple individual com-
plexes containing cell cycle proteins we used the chemical
cross-linker disuccinimidyl suberate (DSS) to preserve
protein-protein interactions in live cells prior to lysis and
SDS-PAGE. The results were complicated. Strikingly,
CyclinB1 existed in several higher MW complexes upon
wild-type but not inactive R80A Vprv treatment [Addi-
tional file 2A, lanes 5 and 6]. Specifically, prominent
CyclinB1 bands were detected at approximately 80 kD,
117 kD, 170, and 210 kD [Additional file 2A and 2E]. Of
note, these bands were visible but markedly less abundant
in cells that did not receive Vprv (lane 4). This suggests that
CyclinB1 exists in similar complexes in normal cycling T
cells and Vpr simply further induces the high MW weight
complexes. While similar analysis of Cdk1 did not indi-
cate any change in its presence within large protein com-
plexes [Additional file 2B], we did observe prominent
bands at 117 kD (c), 170 kD (b), and 230 kD (a) in cross-
linked cells. The 170 and 230 kD bands correspond to the
MW of bands detected on the CyclinB1 blot, and thus may
represent CyclinB1-Cdk1-containing complexes. Since the
predicted size of a CyclinB1-Cdk1 complex would be
approximately 90 kD and therefore smaller than any of
the cross-linked species, at least one other component or
multiple copies of the proteins must be present within
these complexes.
We next attempted to detect 14-3-3 θ, Vpr, and Cdc25C in
high MW complexes by western blot, but these experi-
ments were unsuccessful. The chemical cross-linking proc-
ess may have impaired detection of these proteins by
altering or masking epitopes. Nevertheless, these proteins
still remain strong candidates for association with
CyclinB1 and Cdk1 based on our immunoprecipitation
experiments. Similar analyses of cells undergoing HIV-1
infection-induced G2,M arrest did not exhibit any increase
in CyclinB1 high MW bands [Additional file 2E, lane 6]
consistent with its tenuous enhanced association with 14-
3-3 during infection (Fig. 2A and 6F). This difference was
found even though the infection was robust (71%
infected; Additional file 2D) and the extent of the G2,M
arrest in HIV-infected cells was greater than that caused by
Vprv [Additional file 2D, inset histograms]. As a positive
control for DSS cross-linking, protein kinase A (PKA) α-
catalytic domain was detected as two high molecular
weight structures around 80–100 kD upon DSS treatment,
consistent with PKA α-catalytic domain heterodimeriza-
tion with other 40–50 kD catalytic and regulatory
domains [46] [Additional file 2F]. Thus, Vpr may cause
the formation of high molecular weight complexes with
cell cycle regulatory proteins but it is unclear whether
these are essential for cell cycle arrest during normal infec-
tion.
To determine if 14-3-3 θ binding to cell cycle regulatory
proteins is a general characteristic of the G2,M phase of the
cell cycle or specific to Vpr arrested cells, we examined
synchronized Jurkat cells using DNA polymerase inhibi-
tion by aphidicolin [47]. Upon release from the drug,
most cells were in G1 with diploid DNA content (Fig. 3B,
bottom row, 0h). By 9 hours, the culture progressed to
predominantly G2,M phase, characterized by tetraploid
DNA, and exhibited a DNA profile similar to cells arrested
by Vprv (Fig. 3B, top row, wt). However, co-IP of Cdk1 and
CyclinB1 with 14-3-3 θ was not enhanced in these cells
(Fig. 3C, IP, 6 and 9 h), despite a slight increase in abun-
dance of these proteins at 6 and 9 hours after release (Fig.
3C, input). Treatment with several chemical inhibitors of
mitosis that cause G2,M blockade by targeting the
cytoskeleton, including demecolcine, nocodazole, and
paclitaxel (taxol) also failed to enhance CyclinB1 or Cdk1
association with 14-3-3 θ (data not shown). Thus, the
induction of a complex between 14-3-3 θ, CyclinB1, and
Cdk1 is specific to Vpr-induced cell cycle blockade.
To confirm that Vpr binding to 14-3-3 θ correlates with its
cell cycle arrest activity, we tested this association in
infected cells expressing endogenous Vpr because the Vpr
interaction with 14-3-3 θ is easier to observe in infected
cells than in Vprv-arrested cells (Fig. 2A). Specifically, we
mutated Vpr within the physiological context of the full
virus HIV-1 NL4-3e-n-GFP  to the inactive R80A point
mutant. These experiments were conducted in a Vif-defi-
cient strain of NL4-3 to eliminate the confounding influ-
ence of the G2,M arrest activity of Vif [26]. Unexpectedly,
R80A mutant Vpr co-immunoprecipitated with 14-3-3 θ
to a similar extent as wild-type Vpr (Fig. 3D, top panel),
even though Vpr G2,M cell cycle blockade was abrogated
(Fig. 3D, bottom panel). Thus the reduced function of
R80A cannot be explained by its inability to bind 14-3-3
θ. Rather, other components normally present in a 14-3-3
θ complex may be eliminated by this inactivating Vpr
mutant. It is also interesting to note that the Vpr co-IP
with 14-3-3 θ was weaker in the absence of Vif in HIV-
infected cells, suggesting that Vif enhances this interac-
tion. This may partly explain the better association of Vpr
to 14-3-3 θ in HIV than in Vprv treated cells (Fig. 2A).
DNA damage induces a similar 14-3-3 θ complex
Multiple components of the DNA damage checkpoint are
involved in Vpr-induced cell cycle blockade, including
Chk1, ATR, and BRCA1 [17,48]. To determine whether
elevated 14-3-3 θ binding to Cdk1 and CyclinB1 may be a
shared feature of Vpr-induced cell cycle blockage and the
mitosis-inhibitory DNA damage response in T lym-Biology Direct 2008, 3:17 http://www.biology-direct.com/content/3/1/17
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phocytes, we examined Jurkat cells arrested in G2,M by
adriamycin [49]. 14-3-3 σ, an isoform not expressed in
lymphocytes, binds Cdk1 during G2,M arrest caused by
adriamycin in the colorectal cancer cell line HCT116 [21],
and thus there is precedent for such an interaction.
Indeed, the association between 14-3-3 θ and both Cdk1
and CyclinB1 increased dramatically following adriamy-
cin treatment for 24, 48 or 72 hours (Fig. 4A, IP). Plk1
binding to 14-3-3 θ was also enhanced, indicating that
mitotic regulatory proteins are specifically elevated in the
induced complex. By contrast, the centrosomal resident
protein, centrin, was constitutively associated with 14-3-3
θ. Adriamycin powerfully activated the DNA damage
checkpoint so that essentially all Jurkat cells accumulated
in G2,M with 4N DNA content within 24 hours of treat-
ment (Fig. 4B, inset). Furthermore, cell viability decreased
from 96% to 80% by 72 hours, indicating emerging toxic-
ity to the DNA damage stimulus (Fig. 4B, dot plot). The
magnitude and slow kinetics of adriamycin-induced
death are similar to cell death caused by virion-delivered
or transfected Vpr, which is usually not apparent until 24–
48 hours after initiation of the G2,M arrest [2,34,50]. Thus
cell cycle dysregulation by both adriamycin and Vpr share
several key features: 1) enhanced 14-3-3 θ binding to
Cdk1, CyclinB1, and Plk1, 2) profound G2,M arrest, and
3) cytotoxicity.
Centrosomal proteins dissociate from 14-3-3 θ during HIV-
induced G2,M arrest
Given the growing connection between the centrosome
and G2,M regulation [42,51,52], we considered the possi-
bility that the altered association between 14-3-3, which
localizes to the centrosome [53], and other cell cycle reg-
ulatory proteins might reflect disrupted centrosomal
localization of these proteins. To test this model, we iso-
lated centrosomes from cytosolic proteins by discontinu-
ous sucrose gradients and determined the abundance of
Cdk1, CyclinB1, Plk1, and 14-3-3 θ. Examination of HIV-
1-infected G2,M arrested cells showed a similar centro-
somal protein profile to that of asynchronous and adri-
Cell cycle regulatory protein binding to 14-3-3 θ is also enhanced during G2,M arrest induced by adriamycin Figure 4
Cell cycle regulatory protein binding to 14-3-3 θ is also enhanced during G2,M arrest induced by adriamycin. Jurkat T cells were treated 
with adriamycin (Adr; 0.2 μg/ml) for 24, 48, or 72 hours (h) or untreated (0) and examined for 14-3-3 θ co-immunoprecipitating (IP) pro-
teins. (A) Western blot analysis of Plk1, CyclinB1, Cdk1, 14-3-3 θ and centrin in whole cell lysates before IP (input) and after 14-3-3 θ IP 
(IP: 14-3-3 θ) at the time of adriamycin treatment indicated. These data are representative of three independent experiments. Although 
the amount of 14-3-3 θ appears less in the untreated (0) time point of the IP, this was not a reproducible finding. (B) Viability of the sam-
ples used in the IP in (A) determined by flow cytometry detection of propidium iodide (PI) exclusion and large size (high forward scatter). 
The percentage of viable cells is indicated. Flow cytometric histograms of the DNA content for each sample determined by propidium 
iodide DNA staining (x-axis) are shown as an inset.
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amycin-treated cells (Fig. 5A and 5C). Plk1, CyclinB1, and
Cdk1 were all highly enriched in the centrosome fraction
(lane 3), characterized by the abundance of centrosomal
proteins, γ-tubulin and centrin. 14-3-3 θ, by contrast, was
primarily found in the cytosol, as it remained in the top of
the gradient (lane 7). However, at darker exposures, 14-3-
3 θ was also detected in the centrosome fraction in HIV-
infected, asynchronous, and adriamycin-arrested cells
(Fig. 5A and 5C, "D" exposure, lane 3). These data suggest
that 14-3-3 θ does in fact localize to the centrosome, as
has been described for other 14-3-3 isoforms [53,54].
Centrosomal location of the θ isoform may be specific to
cells in the G2,M phase, however, consistent with previous
reports of regulated 14-3-3 centrosome localization dur-
ing cell division [53]. Control experiments showed that
the infection was robust (85% of the culture infected) and
caused cell cycle arrest and death (Fig. 5B). Similarly, the
adriamycin-treated culture accumulated in G2,M (Fig.
5D). These data suggest that the general composition of
centrosomes in HIV-infected cells does not differ from
asynchronous or adriamycin-arrested cells with respect to
the cell cycle regulatory proteins Plk1, CyclinB1, Cdk1, or
14-3-3 θ. Vif and Vpr were detected throughout the gradi-
ent (lanes 3–7), which suggests that a small fraction of
these accessory proteins may localize to the centrosome
(Fig. 5A). Thus, enhanced association between 14-3-3 θ
and cell cycle proteins during Vpr arrest cannot be
explained by failure of these proteins to localize to the
centrosomes.
We therefore considered the possibility that the configura-
tion of 14-3-3 and cell cycle regulatory proteins with cen-
trosomal proteins is altered by the presence of Vpr, and
this inhibits normal mitotic activation of Cdk1/CyclinB1
within the centrosome. We tested this hypothesis by co-IP
and found markedly decreased centrin associated with 14-
3-3 θ upon infection with wild-type HIV-1 (Fig. 6A). Plk1,
which also localizes to the centrosome [55], showed a
similar striking reduction in 14-3-3 θ association after HIV
infection. This contrasted with our findings with Vprv and
adriamycin (Figs. 3 and 4). These data indicate that the
normal binding of 14-3-3 θ to centrosomal proteins is
reduced during HIV-1 infection and that viral compo-
nents besides Vpr may alter the composition of a 14-3-3 θ
complex. To determine if impaired 14-3-3 θ binding to
centrin and Plk1 in HIV-1-infected T cells correlated with
cell cycle blockade, we examined HIV-1 mutants lacking
the G2,M arresting proteins, Vpr and Vif. Elimination of
either of these genes alone had only modest effects, but
the combined mutant virus lacking both Vpr and Vif was
severely attenuated in G2,M blocking function (Fig. 6B)
[26]. While wild-type HIV-1 infection resulted in a mas-
sive decrease in 14-3-3 θ-associated centrosomal proteins,
infection with vif-vpr- mutant HIV-1completely restored
Plk1 and centrin association with 14-3-3 θ to levels
observed in uninfected cells (Fig. 6A). Moreover, vpr and
vif single mutant virus infections, which caused little or no
attenuation in G2,M arrest activity, respectively, also
reduced Plk1 and centrin association with 14-3-3 θ,
although less than wild-type virus. Infection efficiencies
were matched between the mutant viral strains with 70–
75% of the culture expressing the HIV-1 provirus (Fig. 6C,
inset) and therefore this difference was not due to ineffi-
cient viral replication of the mutant HIV-1 strains. Taken
together, these results show that the impaired association
between 14-3-3 θ and centrosomal proteins was specific
to HIV-1 infection and directly correlated with the extent
of the G2,M block. Moreover, adriamycin treatment did
not cause a similar dissociation between 14-3-3 θ and cen-
trin (Fig. 4A), and thus this effect is not a general feature
of G2,M arrested cells. We therefore conclude that cell
cycle blockade by the Vif and Vpr proteins during HIV-1
infection disrupted protein associations within the cen-
trosome in a manner that correlated with cell cycle block-
ade.
Importin β binding to CyclinB1, Cdk1, and 14-3-3 θ is 
elevated by Vpr
To determine what other cellular proteins bind 14-3-3 θ
and therefore might affect the activity of cell cycle proteins
associated with the scaffold protein during HIV-1 infec-
tion, we performed mass spectrometry on 14-3-3 θ immu-
noprecipitates from untreated Jurkat whole cell lysates. A
matched isotype control antibody was used to distinguish
non-specific bands in the immunoprecipitate. Intrigu-
ingly, importin β was identified in the 14-3-3 θ-associated
fraction (data not shown). To confirm whether 14-3-3 θ
and importin β form a complex, we measured importin β
in 14-3-3 θ immunoprecipitates and observed low levels
in untreated (mock-infected) cells (Fig. 6D, right panel,
"m"). The association between these proteins was dramat-
ically increased during HIV-1 infection, however (Fig.
6D), while Vprv caused a milder increase in binding. The
G2,M arrest by Vprv and HIV-1 was comparable in this
experiment (Fig. 6E), and therefore the difference in com-
plex induction cannot be explained by the magnitude of
cell cycle block. As in Fig. 2A, the amount of Vpr delivered
by Vprv was very low and, in this case, undetectable (Fig.
6D, input), whereas endogenously produced protein in
productively infected cells was apparent in the cell lysates
and 14-3-3 θ IP. Together, these data suggest that a multi-
protein complex consisting of Vpr, 14-3-3 θ, and importin
β accumulates in infected cells as well as during Vprv
arrest. And since importin β localizes to centrosome-
derived spindle poles during the early stages of mitosis
[56], it is conceivable that these complexes are derived
from centrosomal material.
To test whether CyclinB1 is part of an importin β complex
and if Vpr alters the association between them, we immu-Biology Direct 2008, 3:17 http://www.biology-direct.com/content/3/1/17
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Cell cycle regulatory proteins reside in the centrosome during G2,M arrest induced by HIV-1 infection and adriamycin Figure 5
Cell cycle regulatory proteins reside in the centrosome during G2,M arrest induced by HIV-1 infection and adriamycin. (A) 
Western blot analysis of centrosomes isolated from Jurkat cells infected with NL4-3e-n-GFP (HIV; MOI of 2) for two days. Cen-
trosomes were isolated by discontinuous sucrose gradient and fractions were collected and separated by SDS-PAGE and west-
ern blotted for Plk1, CyclinB1, γ-tubulin, Cdk1, 14-3-3 θ, centrin, Vif, and Vpr. Lanes 1–6 represent fractions from the bottom 
of the gradient upward, with centrosomes most abundant in lane 3. Whole cell lysates were run in lane 8 and volume from the 
top of the gradient equivalent to that used for each fraction was run in lane 7 to demonstrate sedimentation of centrosomal 
proteins through the gradient. "L" indicates a light exposure and "D" indicates a darker exposure of the chemilumigraph of the 
middle part of the gel. (B) Viability (top) and DNA content analysis (bottom) by flow cytometry for the culture in (A; HIV (+)) 
and untreated Jurkats without (-) HIV infection. The percentage of viable cells was determined by propidium iodide (PI) exclu-
sion and high forward scatter and is indicated in the lower right corner. Infection efficiency was measured by GFP expression 
(inset; gated population) and the percentage is indicated. DNA content was measured by flow cytometric detection of DNA 
stained with propidium iodide. The GFP-positive population was analyzed for the HIV-infected culture. (C) Jurkat T cells were 
treated with adriamycin (adr; 0.2 μg/ml; right panel) for two days or grown asynchronously (left panel) and centrosomes were 
isolated by discontinuous sucrose gradients as in (A). Centrosomes were most abundant in lanes 2–3 (untreated cells) or lanes 
3–4 (adriamycin treated cells). Lanes were as described in panel A. (D) Cell cycle flow cytometric analysis of Jurkat cells in (C).
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Reduced 14-3-3 θ association with centrosomal proteins, centrin and Plk1, during HIV-1 infection-induced G2,M arrest Figure 6
Reduced 14-3-3 θ association with centrosomal proteins, centrin and Plk1, during HIV-1 infection-induced G2,M arrest. (A) Jurkat cells 
were mock-infected (-) or infected with NL4-3e-n-GFP derivatives encoding wild-type Vif and Vpr (wt), deleted Vpr (r-), deleted Vif (f-), or 
double deletion of Vpr and Vif (fr-) at an MOI of 1.5. Lysates were harvested two days post-infection and immunoprecipitated as in Fig. 2 
(IP: 14-3-3 θ). Whole cell lysates (input) and IP samples were blotted for Plk1, 14-3-3 θ, centrin, Vif, and Vpr. There appeared to be poor 
transfer of centrin protein at the left edge of the gel (input lanes). The reduced band intensity for this sample does not reflect decreased 
centrin abundance as it was well-represented in the IP and similar experiments showed no changes in centrin expression upon HIV-1 
infection. (B) DNA content analysis of the samples in (A) by propidium iodide staining. HIV-infected samples were pre-gated on GFP+ 
cells for DNA analysis. (C) Viability (large plot) and GFP expression by viable cells (inset) for samples in (A) and (B) were measured by 
flow cytometric detection of propidium iodide (PI) negative, large (high forward scatter) cells and GFP fluorescence (inset histogram), 
respectively, at the time lysates were harvested. Plots correspond to samples directly above in (B). The gates demarcate viable and GFP-
positive cell populations and the percentage of cells within each gate is indicated. (D) Jurkat cells were mock-infected (m), infected with 
Vprv as in (A), or infected with NL4-3e-n-GFP (HIV) and harvested after 40 hours for immunoprecipitation with 14-3-3 θ and immunoblot-
ting with importin β, CyclinB1, 14-3-3 θ, and Vpr. (E) DNA content analysis performed as in (B) is shown for the samples in (D). The inset 
histogram depicts the percentage of GFP+ cells expressing the NL4-3e-n-GFP provirus. The DNA analysis for the HIV-infected sample was 
performed on the gated GFP population indicated. (F) Jurkat cells were mock-infected (m), infected with RT- NL4-3e-n-GFP virions (Vprv) 
to deliver Vpr protein, or treated with adriamycin (adr). Cell lysates (input) were harvested after 40 hours for immunoprecipitation with 
importin β (IP) and immunoblotting with importin β, CyclinB1, Plk1, Cdk1, and Vpr as indicated. (G) Cell cycle analysis is shown for the 
samples in (F) at the time of lysis as measured by propidium iodide DNA staining as in (B).
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noprecipitated importin β in cells blocked in G2,M by
Vprv. Elevated levels of CyclinB1, Plk1, and Cdk1 were
bound to importin β compared to untreated cells (Fig. 6F,
right panel). In addition, Vpr was present in the importin
β IP, consistent with importin β-mediated docking of
HIV-1 pre-integration complexes [57]. Since importin β
mediates nuclear entry of CyclinB1-Cdk1 [58,59],
increased binding among these proteins could simply be
a consequence of G2,M status, during which the mitotic
kinase must be shuttled into the nucleus. However, arrest
by adriamycin did not cause increased importin β-Cdk1
association, despite the more pronounced G2,M block
than that by Vprv  and the enhanced association of
CyclinB1 and Plk with importin β (Fig. 6G and 6F). The
increased binding between Cdk1 and importin β was
observed only in cells arrested in G2M by Vprv, suggesting
that this complex may prevent mitosis possibly by seques-
tering Cdk1. Therefore, the CyclinB1-importin β complex
may be a general characteristic of cells in G2,M, while Vpr
uniquely induces a Cdk1-importin β complex that could
disrupt mitotic progression. Since CyclinB1 is present in
both the 14-3-3 θ and importin β IPs, which also co-IP
with one another, these proteins likely form a large holo-
complex.
Discussion
Our findings confirm that an association between 14-3-3
and Vpr occurs not only in yeast and transfected 293 cells
as observed by Kino et al. [11], but also in HIV-1-infected
Jurkat T cells. However, the σ isoform of 14-3-3, which
was important for Vpr G2,M arrest in 293 cells, is not
expressed in lymphoid tissue. We have determined that in
T lymphocytes, the θ, β, and γ isoforms are most relevant
to Vpr function. Thus 14-3-3 isoforms may perform
redundant functions in different cell types depending on
the isoforms expressed.
In contrast to the yeast two hybrid and human 293 cell
systems [11], we found that Vpr binding to 14-3-3 θ was
independent of its ability to block the cell cycle in Jurkat
cells. The cell cycle arrest Vpr mutant R80A associated
with 14-3-3 θ almost as efficiently as wild-type Vpr in HIV-
1 infected cells. Since 14-3-3 isoforms are known to func-
tion as homo- and heterodimers, poor interaction
between R80A Vpr and 14-3-3 θ in yeast may be due to
lack of an additional 14-3-3 isoform that stabilizes R80A
binding in mammalian cells. And since 14-3-3 isoforms
other than σ were not individually examined in 293 cells
by Kino et al., these findings may not reflect Vpr binding
interactions with other isoforms or in lymphoid cells
which lack 14-3-3 σ. Rather than a 14-3-3 binding defect,
we show that cell cycle arrest mutants are impaired for the
ability to recruit G2,M regulatory proteins to 14-3-3. In
addition, this implicates residues other than phosphor-
ylated S79 of Vpr in binding 14-3-3 θ since the R80A
mutation prevents S79 phosphorylation [60]. Other 14-3-
3 isoforms may bind this residue, though, and be respon-
sible for transporting Cdk1, CyclinB1 in heterodimeric
14-3-3 complexes.
Vpr binding to 14-3-3 has previously been shown to
increase cytoplasmic Cdc25C, presumably independent
of the Cdc25C phosphoserine residue that usually medi-
ates 14-3-3 binding [11]. However, we were unable to
detect any redistribution of phospho-Cdc25C caused by
Vprv or HIV-1 infection. Since the prior work was based on
overexpression of mutant Cdc25C lacking the phosphor-
ylation site required for 14-3-3 binding, it is possible that
Vpr affects only the unphosphorylated Cdc25C popula-
tion, which was not examined in our studies. Vpr and
HIV-1 infection did increase Cdc25C association with 14-
3-3, consistent with the idea that Vpr influences 14-3-3-
Cdc25C binding. Thus although the distribution of
endogenous Cdc25C was not significantly affected by Vpr,
altered Cdc25C-14-3-3 binding could impair Cdc25C
activation of Cdk1 and prevent normal progression
through mitosis.
The prevailing model of Vpr-induced G2,M arrest entails
inhibition of Cdk1, as evidenced by an increase in the
phosphorylated inactive form of the enzyme and
impaired kinase activity [5-7]. Despite numerous
attempts, we were unable to detect an increase in phos-
phorylated, inactive Cdk1 in Jurkat cells blocked in G2,M
by either Vprv or HIV-1 infection. Again, this discrepancy
may be due to cell-type specific differences, as previous
work on Cdk1 inactivation by Vpr was performed in HeLa
epithelial cells. Cell cycle regulation in lymphoid tissue is
distinct from that in other mammalian cells during
embryogenesis, as hematopoietic cell proliferation defects
in Cdk4 and Cdk6 double knockout mice are not exhib-
ited in other cell types [61]. Thus, Cdk1 may play a differ-
ent role in cell division in epithelial and lymphoid cells.
Likewise, a Vpr-induced proliferation block in HeLa cells
may be characterized by dramatic inhibition of Cdk1
while other Cdks are more significant in T cells. This is
supported by the fact that overexpression of constitutively
active Cdk1 blocks Vpr-induced G2,M arrest in 293 fibrob-
lasts [5], but not Jurkat cells (data not shown). It is also
possible that only a small, critical subset of cellular Cdk1
is inactive, and thus examination of total cell lysates might
not reveal this distinct population. In addition, since Jur-
kat cells are derived from a human T cell leukemia sample
that was adapted for continuous growth in culture, its cell
cycle regulatory machinery may not be representative of
primary T cells. Thus it will be important to confirm these
findings in primary cells.
Although we did not observe increased Cdk1 phosphor-
ylation by Vpr or HIV-1 infection, the association of Cdk1Biology Direct 2008, 3:17 http://www.biology-direct.com/content/3/1/17
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and CyclinB1 with 14-3-3 was significantly altered during
Vpr-induced G2,M arrest. Similar increases in Cdk1-14-3-
3 binding during DNA damage induced G2,M arrest are
accompanied by cytoplasmic sequestration of Cdk1-
CyclinB1 complexes [21]. However, this was not the case
in Vpr- or HIV-1-induced G2,M arrest. Hence, Vpr
increases 14-3-3-Cdk1 binding, presumably as a result of
Vpr associating with 14-3-3, but appears to attenuate its
activity by a mechanism that does not rely on cytoplasmic
sequestration. Since the association of several other G2,M
regulatory proteins with 14-3-3 also increased, Vpr may
nucleate a large multi-protein complex that prevents
proper activation of Cdk1. For example, Cdk1 inhibitor
kinases, Wee1 or Myt1, could have greater activity on
Cdk1 in the complex. This is supported by the apparent
increase in phosphorylated, inactive Cdk1 associated with
14-3-3 θ. Furthermore, Wee1 also binds 14-3-3 [62-64],
although we were unable to detect Wee1 in 14-3-3 immu-
noprecipitates (data not shown). The fact that the overall
levels of phospho-Cdk1 were unaltered in Vpr-arrested
cells could also indicate that the 14-3-3-Cdk1 complex
dominantly interferes with unbound Cdk1. In particular,
hyperphosphorylated, presumably active CyclinB1, which
is required for Cdk1-CyclinB1 nuclear import, was
enriched in the 14-3-3 complex in HIV-1-arrested cells,
and thus might be unavailable for facilitating nuclear
entry of other Cdk1 molecules. Alternatively, a CyclinB1
activating kinase may also be complexed with 14-3-3 and
restrained from acting upon CyclinB1 not associated with
14-3-3. Such mechanisms would prevent Cdk1 from
entering the nucleus and phosphorylating substrates
required for mitotic progression.
It remains unclear why CyclinB1 binding to 14-3-3 θ dur-
ing HIV-1 infection is variable and occasionally inconsist-
ent with the enhancement induced by Vprv, but other viral
proteins may be involved [26,32]. Similarly, Vprv but not
HIV-1-infected cell Vpr expression generated high MW
CyclinB1/Cdk1 complexes. Thus other HIV-1 proteins
may interfere with or disrupt this activity. Alternatively,
these complexes may originate from virus-producing cells,
as many cell cycle regulatory proteins are packaged into
HIV-1 virions. Enrichment of a cell cycle regulatory com-
plex containing CyclinB1 within HIV-1 virions and subse-
quent delivery of this complex into target cells could
substantially increase the amount of higher-order
CyclinB1 in target cells. Since these complexes were not
consistently amplified in HIV-1-blocked or synchronous
G2,M cells, they do not appear to be a general feature of
G2,M-phase cells. We therefore conclude that induction of
CyclinB1 multi-protein complexes is specific to Vpr-
induced G2,M blockade, and this may serve to negatively
regulate CyclinB1 activity and maintain the G2,M block-
ade.
The centrosome is emerging as an important cell cycle reg-
ulatory organelle where active Cdk1-CyclinB1 is first
detected [42]. Moreover, 14-3-3 isoforms ε and γ localize
to centrosomes [53], along with several other G2,M regu-
latory proteins. Our data indicate that 14-3-3 θ binding to
centrosomal proteins is significantly impaired during
HIV-1-induced G2,M arrest. This does not appear to reflect
poor 14-3-3 localization to centrosomes, but rather a
more subtle disruption in the specific binding of 14-3-3 to
centrosomal proteins within the centrosome. This could
have important implications for Cdk1-CyclinB1 activa-
tion and nuclear import. For example, binding of the 14-
3-3 scaffold protein to centrosomal proteins may form a
crucial platform that facilitates Cdk1-CyclinB1 biochemi-
cal modification and activation. Increased Cdk1,
CyclinB1, or Vpr binding to 14-3-3 could impair the abil-
ity of 14-3-3 to interact with centrosomal proteins, which
may be required for proper activation of Cdk1 or
CyclinB1. Plk1, in particular, phosphorylates CyclinB1,
although it is not clear how this affects CyclinB1 activity
or how it could be regulated by centrin [42,65]. It is also
possible that nuclear import of Cdk1-CyclinB1 occurs via
the centrosome, which may serve as a cytoplasmic-nuclear
shuttling vessel [52], and the loss of 14-3-3 binding to
centrosomal proteins reduces transport efficiency.
Although the θ isoform of 14-3-3 had not previously been
found to localize to the centrosome [53,54], 14-3-3 θ
expression in the centrosome may be unique to certain
phases of the cell cycle or to specific cell types. Together,
these findings suggest that normal 14-3-3 activity within
the centrosome is disturbed in HIV-1 infection-induced
G2,M arrest and may be responsible for impaired Cdk1
activation. Further evidence that Vpr causes rearrange-
ment, rather than dislocation, of normal protein assem-
blies is the enhanced association of cell cycle regulatory
proteins with importin β, which governs nuclear import
and export as well as various functions related to the
mitotic spindle.
Vpr is known to cause accumulation of multiple centro-
some-like structures and aberrant mitotic spindles
[43,66,67]. It is presently not clear how this relates to the
reduced 14-3-3-centrosome binding observed in our stud-
ies. Abnormal centrosomal duplication during HIV-1
infection apparently requires Vpr [67], whereas HIV-1
lacking Vpr still disrupted 14-3-3 binding to centrosomal
proteins, presumably due to Vif. Thus, these two effects on
the centrosome are likely unrelated. Since DNA damage-
induced G2,M arrest increases association between 14-3-3
and the centrosomal kinase, Plk1, HIV-1 arrested cells are
distinct from other G2,M-arrested cell phenotypes.
Many of the changes in the association between 14-3-3
and cell cycle regulatory proteins in Vpr arrested cells were
also observed upon G2,M blockade caused by adriamycin-Biology Direct 2008, 3:17 http://www.biology-direct.com/content/3/1/17
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induced DNA damage. This supports the model of Vpr
activation of the ATR DNA damage response [17],
although it is not clear how this relates to 14-3-3. Consist-
ent with this possibility, our data confirmed that the ATR
substrate, Chk1, is important for Vpr-induced G2,M arrest.
In addition, we provide the first evidence that Chk1 as
well as 14-3-3 are of central importance for Vpr cell cycle
block in the context of actual HIV-1-infection. Future
studies examining the combined effect of Chk1 and 14-3-
3 loss will help to determine if these proteins are involved
in separate or related mechanisms.
Conclusion
Although many different mechanisms have been pro-
posed to explain Vpr G2,M cell cycle blockade, the data
presented herein provide strong support for a 14-3-3-
dependent process involving abnormal associations of
cell cycle regulatory proteins. Silencing of 14-3-3 θ, in par-
ticular, decreased the arrest induced by both virion-associ-
ated Vpr and endogenous Vpr during HIV-1 infection in
Jurkat T cells. Although 14-3-3 is known to negatively reg-
ulate mitosis through cytoplasmic sequestration of Cdk1
and Cdc25C, this mechanism does not appear to be
involved in the Vpr arrest. Rather, multiple G2,M regula-
tory proteins accumulate in a complex with 14-3-3 θ,
including CyclinB1, Cdk1, and Cdc25C. Similar protein-
protein interactions were observed in cells arrested in
G2,M by DNA damage, but not synchronous G2,M cells,
suggesting that this process is likely the cause rather than
a consequence of G2,M status. Intriguingly, the binding of
several centrosomal proteins to 14-3-3 θ was dramatically
reduced in HIV-1-arrested cells, while importin β
increased in association with CyclinB1, Cdk1, and 14-3-3
θ under Vpr arrest conditions. Combined, these data sup-
port a model in which mitotic proteins are inactive due to
improper post-translational modification conditions in
the centrosome or incorporation into a protein complex
that prevents access to substrates.
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Reviewers' comments
Reviewer's report 1
David Kaplan, Case Western Reserve University
I have reviewed your manuscript entitled, "14-3-3 theta
binding to cell cycle regulatory factor is enhanced by HIV-
1 Vpr". My comments follow:
Your manuscript is terrific. You have identified an impor-
tant area of investigation, the interaction of HIV-1 Vpr
with the host cell cycle apparatus, and have made credible
progress in your study. Your work has the potential to lead
to a greater understanding of HIV-1 pathogenesis, to a
therapeutic target for treatment of the infection, and to
appreciation for the cellular targets of Vpr. Most impor-
tantly, you have assessed the interaction of Vpr with a T
cell instead of an epithelial cell. The data presented are
convincing. You have combined flow cytometric cell cycle
analysis with immunoprecipitation and siRNA inhibition
in a clever way. Finally, the manuscript is written in a clear
and concise way. In summary, this manuscript represents
a significant contribution to the scientific literature.
Nevertheless, I have several suggestions that you may
want to consider for revising your manuscript. Specific
comments follow:
1. A major feature of this manuscript involves the use of
Jurkat cells (which derive from T cells) instead of yeast or
transfected 293 cells (which derive from human kidney).
Since HIV-1 infects T cells and since cells from different
origins express different molecules, there is a powerful
rationale for the use of the Jurkat cells. Differential expres-
sion of 14-3-3 isoforms emphasizes this choice. Neverthe-
less, a similar argument could be used in regards to Jurkat
cells. Jurkat is derived from a human T cell leukemia sam-
ple. It was adapted for continuous growth in culture. It is
not the same as primary T cells or nontransformed T cells.
In fact, I think it is a misnomer to refer to Jurkat cells as T
cells (although I understand that the literature is replete
with this usage). I would agree that a study of primary T
cells or nontransformed T cell lines or clones should be
considered a separate investigation or a continuation of
this investigation. However, there is no clear exposition of
this point in the manuscript. I find a single sentence that
addresses the issue which appears right before the conclu-
sion. This sentence does not indicate that Jurkat cells have
been adapted for continuous growth in culture and conse-
quently may have altered the expected patterns of expres-
sion of cell cycle proteins. A more extensive consideration
of this point would be appropriate in this manuscript.
Author's response
We agree that using the Jurkat cell line as a model system
for studying regulation of the cell cycle introduces impor-Biology Direct 2008, 3:17 http://www.biology-direct.com/content/3/1/17
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tant limitations due to its origins as a leukemia sample
adapted for continuous growth in culture. We have elabo-
rated on this point in the conclusions and adjusted the ter-
minology when referring to Jurkat cells as suggested by the
reviewer.
2. There is no consideration of statistics in the manuscript.
Error bars are not supplied. Consequently, I looked for
consistency in the results presented. For instance, in Fig-
ure 1C siRNA for 14-3-3 theta clearly decreased the G2
arrest induced by infection with NL4-3 vif-, but in Figure
1F siRNA for 14-3-3 theta induced only a slight change in
the G2 arrest induced by infection with NL4-3 vif-.
Author's response
The reviewer expresses concern over the level of variation
between two siRNA knockdown experiments shown in
different panels within Figure 1. These differences result
from varying levels in the efficiency of gene knockdown
and HIV-1 infection. Since the experiment in Fig. 1F was
less representative of multiple replicates, and for reasons
described in point #4 below, we removed this panel. As
stated in the figure legend, Fig. 1B and 1C are representa-
tive of six independent experiments. For example, Fig. 1C
and Fig. 1G (formerly Fig. 1I) are highly consistent.
3. In Figure 1D, siRNA for Chk1 appears to have signifi-
cantly inhibited expression of 14-3-3 theta.
Author's response
Although the amount of 14-3-3 θ appears slightly reduced
in the Chk1 knockdown in Fig. 1D, this was not observed
in multiple repeats of the experiment, including Fig. 1F,
and was thus likely a blotting defect.
4. In Figure 1, the targeting of the various isoforms of 14-
3-3 by siRNA does not appear to have produce much spe-
cificity in effect. For instance, in Figure 1G knockdown of
beta has decreased both beta and theta expression. Inhibi-
tion of tau has decreased theta expression. Inhibition of
gamma appears to have cause a decrease in Chk1. You
have indicated that the antibodies to the nu and zeta iso-
forms crossreact with other isoforms. It may be best to
reconsider these data. I am not sure that they add much to
the manuscript.
Author's response
We agree that the knockdown data of 14-3-3 isoforms in
Fig. 1F and 1G are complicated by the possible poor
siRNA specificity. We have removed these panels as sug-
gested by the reviewer.
5. I do not understand why there are no GFP positive
events in Figure 2B, middle panel, since the Vpr-v vector
has GFP.
Author's response
Samples treated with Vprv simply receive virion-associated
proteins and do not express any genes encoded by the
viral genome due to the lack of a functional RT protein.
There is insufficient GFP packaged in the viral particle to
cause recipient cells to fluoresce. We have added this
explanation to the results for clarity.
6. On page 20, you suggest that the monoclonality of the
antibody to Chk1 argues against cross-reaction. However,
I believe that argument is not correct. Monoclonal anti-
bodies are more prone to cross- reaction than polyclonal
antibodies. All antibodies are cross- reactive because the
structure of the antibody binding site allows for different
structures to be bound. The cross-reactions of different
antibodies would not expect to be the same so cross- reac-
tion for polyclonal antibodies is not likely to cause a prob-
lem. For monoclonal antibodies cross-reactions can be a
problem because all the antibody present has the same
cross-reaction.
Author's response
We agree with reviewer's point and removed the comment
regarding the monoclonal origin of the antibody.
7. In Figure 3D, the flow cytometric panels should be
labeled more clearly.
Author's response
Due to space constraints, it is not possible to add addi-
tional text to label the histograms in Fig. 3D. We clarified
in the figure legend that the numbers within each histo-
gram correspond to the lane numbers in the blots directly
above.
Reviewer's report 2
Nathaniel R. Landau, New York University School of Medicine
The Vpr accessory protein of HIV-1 and other lentiviruses
has been found to associate with several cellular proteins
and it is not yet clear which of these is physiologically rel-
evant.  Bolton et al. show that Vpr can form a complex
with 14-3-3, a series of protein scaffolds that directs the
cellular localization of cyclin dependent kinases.  Vpr
caused 14-3-3 to associate more strongly with Cdk1,
Cdc25C and cyclin B1.  In addition, Vpr caused 14-3-3 to
bind less well to Plk1 and centrin in the centrosome.
These findings shed light on how Vpr affects the cell cycle.
It will be of interest to understand whether the effects of
Vpr on 14-3-3 are caused by the association of Vpr with
DDB1 containing E3 ubiquitin ligases or whether this is
an independent function for Vpr.  It will also be of interest
to understand how these associations contribute to virus
replication and pathogenesis.      Biology Direct 2008, 3:17 http://www.biology-direct.com/content/3/1/17
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There is a lot of good work described in the study. It is well
written, thorough and novel. However, there are some
weaknesses that need to be addressed. The manuscript is
too long. There is a tremendous amount of data presented
in the 7 figures, each of which contains several panels. The
results, discussion and figure legends, although scholarly,
are lengthy. Even the aficionados may not want to read
them. The authors should decide on a few panels that can
be deleted and a few that can be moved to the Supple-
ment. The results and discussion should be shortened to
make a few major points. While the authors have done a
huge amount of work, if the paper is too long, its impact
will be like a tree falling in the forest. There needs to be a
clear take-home message conveyed by the manuscript.   
Author's response
The reviewer suggests shortening the length of the Results
and Discussion sections to better focus the manuscript.
We have eliminated a few figure panels and moved some
to the supplemental material. We have also edited the text
of the Results and Discussion to be more concise.     
Secondly, there were recently a set of important papers
published on Vpr that show its interaction with a DDB1
containing E3 ubiquitin ligase. The authors make no men-
tion of this work. This may leave the impression that the
authors are somewhat disconnected from the rest of the
Vpr field. The authors may want to at least mention this
work.   
Author's response
We have added a comment to the introduction mention-
ing the recent published body of work on Vpr binding to
DDB1 and its relevance to the cell cycle block activity of
Vpr.     
Thirdly, the authors portray the early work on Vpr that
shows its role in nuclear import as established fact. It is
not. The authors may want to soften their statements
about this model for Vpr function, as it is not generally
accepted in the field.   
Author's response
As suggested by the reviewer, we have softened the tone of
any statements regarding the role of Vpr in mediating
import of the virus into the nucleus.
Reviewers' report 3
Yan Zhou, Johns Hopkins University School of Medicine
In "14-3-3 θ binding to cell cycle regulatory factors is
enhanced by HIV-1 Vpr", Bolton et al. investigate the role
of scaffold protein 14-3-3 in Vpr-mediated cell cycle arrest
in Jurkat T cells. A previous study using the yeast two-
hybrid system and non-lymphocyte cell lines suggested
that Vpr directly binds to 14-3-3 and facilitates the cyto-
plasmic sequestration of Cdc25C. The siRNA knockdown
experiment in this study convincingly demonstrates that
endogenous 14-3-3, particularly 14-3-3 θ, plays an impor-
tant role in Vpr-mediated cell cycle arrest.
The authors performed immunoprecipitation experi-
ments to probe the components of 14-3-3 θ complex
formed upon Vpr-induced cell cycle arrest. In addition to
single-round viral infection, the authors took the elegant
approach of introducing virion associated Vpr (Vprv) into
cells with an RT-minus virus to focus on Vpr-mediated cell
cycle arrest. Control experiments included mock infected
cells, cells synchronized by aphidicolin, cells arrested at
G2,M by adriamycin, and cells infected with virus carrying
an inactive mutant Vpr. The authors demonstrated that
enhanced binding of cell cycle regulators to 14-3-3 θ is
characteristic of cells arrested at G2,M, although the asso-
ciation of several components with 14-3-3 θ varied among
cells arrested by Vprv, HIV-1 infection, and adriamycin. In
case of Vprv, enhanced binding of cdk1, Cdc25C, and
CyclinB1 to 14-3-3 θ was observed.
The direct binding of Vpr to 14-3-3 θ would suggest an ini-
tiating role for the multi-protein complex in Vpr-medi-
ated cell cycle arrest. The authors could not prove this in
cells arrested by Vprv. Instead, they found that both active
and inactive Vpr bound to 14-3-3 θ in infected cells.
Therefore, it remains possible that the complex executes
rather than initiates Vpr-induced G2,M arrest.
The authors demonstrated that the formation of the
multi-protein 14-3-3 θ complex correlates with G2,M
arrest. However, previously reported cytoplasmic seques-
tration of Cdk1 and Cdc25C as well as hyperphosphoryla-
tion of Cdk1 was not observed in this system, probably
due to cell type specific regulation of cell cycle. In an effort
to explore the mechanism underlying cell cycle arrest, the
authors demonstrated that the 14-3-3 θ complex localizes
to centrosomes in HIV-1 infected cells and cells treated
with adriamycin. Interestingly, the binding of 14-3-3 θ to
centrosomal proteins, centrin and Plk1, is disrupted in
HIV-1 infection but not in adriamycin treated cells. It will
be informative to test if impaired association between
centrin and 14-3-3 θ also occurs in cells treated with Vprv.
The authors further demonstrated enhanced binding of
the nuclear transport and spindle assembly protein
importin θ to the 14-3-3 θ complex in cells arrested by
Vprv and HIV-1 infection. In light of these results, the
authors proposed that abnormal assembly of 14-3-3 θ
complex affects the activity of cell cycle regulators or their
access to substrates.
This study has revealed the important role of 14-3-3 θ in
orchestrated events in Vpr-induced G2,M arrest. RecentBiology Direct 2008, 3:17 http://www.biology-direct.com/content/3/1/17
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studies suggested the involvement of damaged DNA bind-
ing protein 1 and Cul4A in Vpr-induced cell cycle arrest. It
will be interesting to determine the spatial and temporal
relationship between ubitquitin-ligase complex, Vpr, and
the 14-3-3 θ complex described in this study. It will also
be important, as the authors point out at the end of this
manuscript, to confirm all of these findings in primary
CD4+ T cells.
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